Today: 21 May 2026
Ondas (ONDS) stock slides again after J Capital report; Rotron deal and Singapore Airshow in focus
5 February 2026
2 mins read

Ondas (ONDS) stock slides again after J Capital report; Rotron deal and Singapore Airshow in focus

New York, February 5, 2026, 14:34 (EST) — Regular session

  • Ondas shares dropped roughly 9%, settling at $8.77 in afternoon trading, following a range between $8.56 and $9.80 earlier.
  • The stock plunged further following a bearish report from J Capital Research released the previous day
  • Ondas revealed an Asia-Pacific defense deal this week and struck a deal to acquire UK-based Rotron Aero

Shares of Ondas Inc took a hit on Thursday, dropping roughly 9% as the small-cap defense drone and wireless-networking firm continued its steep slide. By mid-afternoon, the Nasdaq-listed stock was trading down 9.4% at $8.77, with around 76 million shares changing hands.

The slide is significant given Ondas’s recent surge on rapid-fire deal news, leaving the tape jittery. Traders who pushed the stock up earlier this week are now questioning if new contract announcements can offset concerns over how the company will finance its growth.

The tension has taken center stage. Bulls want to see signed orders and delivery timelines, while skeptics focus on dilution — the selling of new shares that cuts into current investors’ stakes — and the risk that acquisitions might take a while to yield results.

J Capital Research, a self-described short-seller, released a note Wednesday titled “Ondas Won’t Live Up to the Hype.” It slammed Ondas’ strategy as “high-priced, money-losing acquisitions funded by massive share dilution,” accusing the company of “incinerating cash and value” while pointing to past fundraising rounds and insider sales. J Capital Research

Ondas shifted focus with news Tuesday that its Airobotics unit landed a “strategic” deal with a government defense client in the Asia-Pacific region. The contract covers autonomous unmanned aerial systems — drones — aimed at national security tasks. Initial deliveries are slated for this year, with potential follow-up orders. CEO Eric Brock noted demand in the area is “accelerating,” while OAS co-CEO Oshri Lugassy described the platforms as “combat proven.” Ondas Inc.

Ondas revealed the previous day that it had signed a definitive agreement to acquire Rotron Aero, a UK-based developer specializing in unmanned systems and long-range autonomous platforms. The deal involves a mix of cash and stock. Brock described the acquisition as a move that would “accelerate” Ondas’ drive toward full “end-to-end autonomous mission capability.” Corporate development head Mark Green added that the purchase would broaden the company’s presence in the UK and NATO markets. According to a Form 8-K filing, the deal is still pending customary conditions and regulatory approvals.

Ondas dropped 14.7% on Wednesday following the J Capital report, per Investing.com, with the downward pressure extending into Thursday.

Ondas highlighted its Asia-Pacific award at the Singapore Airshow, which continues through Feb. 8. Investors are eager for specifics on contract size, delivery timing, and if the company can secure additional orders while present in Singapore.

The downside scenario is straightforward. The Asia-Pacific deal didn’t reveal the customer or the dollar amount involved, and the Rotron deal hasn’t closed yet. Any regulatory hiccup, integration issues, or fresh fundraising round could keep the stock volatile.

Traders are now turning their attention to new updates from the Singapore Airshow before it closes on Sunday, along with any filings that clarify the timelines and details of the Rotron acquisition.

Stock Market Today

  • Q1 Earnings Analysis: Pegasystems Lags, Appian Leads Automation Software Stocks
    May 20, 2026, 8:03 PM EDT. As Q1 earnings wrap up in the automation software sector, Pegasystems (NASDAQ:PEGA) posted a disappointing 9.6% revenue decline to $430 million, missing analyst estimates by 7.3%. Its stock dropped 11.8% post-report. Conversely, Appian (NASDAQ:APPN) showed robust growth with a 21.5% revenue increase to $202.2 million, beating expectations by 5.6%, yet its shares fell 9.2%. The sector overall saw revenues exceed consensus by 0.8%, but stocks fell 6.5% on average after earnings. Pegasystems' approach centers on AI-driven workflow automation, while Appian offers a low-code platform for complex processes. These contrasting performances highlight varied market reactions despite solid fundamental advances in automation software driven by AI and machine learning integration.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Boston Scientific stock rebounds after brutal selloff — what Wall Street watches next
Previous Story

Boston Scientific stock rebounds after brutal selloff — what Wall Street watches next

S&P Global stock slides again as “Mobility Global” spin-off rebrand puts SPGI in the spotlight
Next Story

S&P Global stock slides again as “Mobility Global” spin-off rebrand puts SPGI in the spotlight

Go toTop